Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Semena (befotertinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Betta Pharma, InventisBio

Drug class:

EGFR inhibitor, Tyrosine kinase inhibitor

Related drugs:

‹

Tyrosine Kinase inhibitors (0)

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

zorifertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

Tyrosine Kinase inhibitors (0)

›

EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	befotertinib Sensitive: B - Late Trials befotertinib Sensitive : B	befotertinib Sensitive: B - Late Trials befotertinib Sensitive : B
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	befotertinib Sensitive: B - Late Trials befotertinib Sensitive : B	befotertinib Sensitive: B - Late Trials befotertinib Sensitive : B
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	befotertinib Sensitive: C2 – Inclusion Criteria befotertinib Sensitive : C2	befotertinib Sensitive: C2 – Inclusion Criteria befotertinib Sensitive : C2